Groupe Hospitalier Diaconesses Croix Saint Simon
- Address
- lock Available on a paid plan
Neoplasms
The oncology department at Groupe Hospitalier Diaconesses Croix Saint Simon is advancing cancer care through trials on breast neoplasms, prostate adenocarcinoma, and colon carcinoma, evaluating targeted agents, neo‑adjuvant regimens, and circulating tumor DNA‑guided strategies.
- Targeted endocrine therapy for hormone‑responsive breast cancer
- Neo‑adjuvant FOLFOX chemotherapy in resectable colon cancer
- ctDNA‑directed treatment selection after surgery
- Comparative study of ADT plus darolutamide versus ADT alone
- Evaluation of novel oral SERD imlunestrant in early breast cancer
Multidisciplinary collaboration across medical oncology, surgery, and radiology drives innovative approaches to improve survival and quality of life.
Respiratory Tract Diseases
A phase III investigation at the site focuses on patients with severe community‑acquired pneumonia, testing the immunomodulator trimodulin to reduce 28‑day all‑cause mortality.
- Immunomodulatory therapy for severe pneumonia
- Hospitalized adult patient outcomes
- Mortality and safety endpoints
- Biomarker and inflammatory response analysis
- Integration with standard antimicrobial care
The pulmonary unit works closely with intensive‑care specialists to bring novel treatments to critically ill patients.
Musculoskeletal Diseases
Researchers are evaluating secukinumab in individuals with moderate to severe rotator cuff tendinopathy, aiming to alleviate shoulder pain and improve functional scores by week 16.
- IL‑17 inhibition for tendon inflammation
- Physical symptom relief and mobility enhancement
- Patient‑reported outcome measures
- Safety and tolerability monitoring
- Comparative analysis against placebo
Orthopedic and rheumatology teams jointly manage the trial to address unmet needs in musculoskeletal health.
Digestive System Diseases
The centre conducts studies on colon carcinoma, including age‑adapted neo‑adjuvant chemotherapy and ctDNA‑guided adjuvant strategies, to enhance disease‑free survival after surgery.
- Neo‑adjuvant FOLFOX in elderly patients
- ctDNA surveillance for recurrence risk
- Optimization of adjuvant chemotherapy selection
- Surgical outcome comparisons
- Long‑term follow‑up of disease‑free intervals
A collaborative effort between surgical oncology, medical oncology, and pathology supports personalized colorectal cancer care.
Bacterial Infections and Mycoses
An infection‑focused trial investigates the safety and efficacy of rifampicin in treating C. spp. prosthetic joint infection, seeking to improve eradication rates while preserving joint function.
- Antibiotic safety profiling in prosthetic joint infections
- Efficacy assessment of rifampicin regimens
- Monitoring of microbial resistance patterns
- Functional outcome evaluation post‑treatment
- Integration with surgical debridement protocols
Infectious disease specialists partner with orthopedic surgeons to refine management of complex prosthetic infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 18 therapeutic areas and 15 of 156 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 143 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Groupe Hospitalier Diaconesses Croix Saint Simon
lock Showing 1 of 98 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Long-Term follow-up Study to evaluate safety and tolerability of olipudase alfa in patients who completed the DFI12712 or the LTS13632 Study in France - PTA17397 | Sanofi Winthrop Industrie | Phase II | Not Recruiting | Nov 2021 | Apr 2025 |
IMP list
lock Showing 1 of 156 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 18 | Unknown | 2017-03-27 | 2026-06-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.